S&P 500   4,532.92 (-0.07%)
DOW   35,546.16 (-0.18%)
QQQ   374.96 (+-0.01%)
AAPL   149.20 (-0.04%)
MSFT   307.93 (+0.17%)
FB   339.75 (-0.30%)
GOOGL   2,827.22 (-0.29%)
TSLA   887.71 (+2.53%)
AMZN   3,417.22 (+0.06%)
NVDA   222.59 (+0.71%)
BABA   179.22 (+1.15%)
NIO   40.30 (+1.31%)
CGC   14.34 (+1.63%)
GE   105.48 (-0.49%)
AMD   117.42 (+0.88%)
MU   68.10 (-0.25%)
T   26.16 (+0.96%)
F   16.53 (+3.05%)
ACB   7.74 (+1.04%)
DIS   172.07 (+0.89%)
PFE   42.75 (-0.12%)
BA   217.30 (+0.52%)
AMC   41.36 (+1.17%)
S&P 500   4,532.92 (-0.07%)
DOW   35,546.16 (-0.18%)
QQQ   374.96 (+-0.01%)
AAPL   149.20 (-0.04%)
MSFT   307.93 (+0.17%)
FB   339.75 (-0.30%)
GOOGL   2,827.22 (-0.29%)
TSLA   887.71 (+2.53%)
AMZN   3,417.22 (+0.06%)
NVDA   222.59 (+0.71%)
BABA   179.22 (+1.15%)
NIO   40.30 (+1.31%)
CGC   14.34 (+1.63%)
GE   105.48 (-0.49%)
AMD   117.42 (+0.88%)
MU   68.10 (-0.25%)
T   26.16 (+0.96%)
F   16.53 (+3.05%)
ACB   7.74 (+1.04%)
DIS   172.07 (+0.89%)
PFE   42.75 (-0.12%)
BA   217.30 (+0.52%)
AMC   41.36 (+1.17%)
S&P 500   4,532.92 (-0.07%)
DOW   35,546.16 (-0.18%)
QQQ   374.96 (+-0.01%)
AAPL   149.20 (-0.04%)
MSFT   307.93 (+0.17%)
FB   339.75 (-0.30%)
GOOGL   2,827.22 (-0.29%)
TSLA   887.71 (+2.53%)
AMZN   3,417.22 (+0.06%)
NVDA   222.59 (+0.71%)
BABA   179.22 (+1.15%)
NIO   40.30 (+1.31%)
CGC   14.34 (+1.63%)
GE   105.48 (-0.49%)
AMD   117.42 (+0.88%)
MU   68.10 (-0.25%)
T   26.16 (+0.96%)
F   16.53 (+3.05%)
ACB   7.74 (+1.04%)
DIS   172.07 (+0.89%)
PFE   42.75 (-0.12%)
BA   217.30 (+0.52%)
AMC   41.36 (+1.17%)
S&P 500   4,532.92 (-0.07%)
DOW   35,546.16 (-0.18%)
QQQ   374.96 (+-0.01%)
AAPL   149.20 (-0.04%)
MSFT   307.93 (+0.17%)
FB   339.75 (-0.30%)
GOOGL   2,827.22 (-0.29%)
TSLA   887.71 (+2.53%)
AMZN   3,417.22 (+0.06%)
NVDA   222.59 (+0.71%)
BABA   179.22 (+1.15%)
NIO   40.30 (+1.31%)
CGC   14.34 (+1.63%)
GE   105.48 (-0.49%)
AMD   117.42 (+0.88%)
MU   68.10 (-0.25%)
T   26.16 (+0.96%)
F   16.53 (+3.05%)
ACB   7.74 (+1.04%)
DIS   172.07 (+0.89%)
PFE   42.75 (-0.12%)
BA   217.30 (+0.52%)
AMC   41.36 (+1.17%)
CVE:ACST

Acasti Pharma Stock Forecast, Price & News

C$2.30
+0.07 (+3.14 %)
(As of 10/21/2021 09:42 AM ET)
Add
Compare
Today's Range
C$2.23
C$2.30
50-Day Range
C$0.50
C$3.39
52-Week Range
C$1.84
C$12.40
Volume2,802 shs
Average Volume41,256 shs
Market CapitalizationC$101.86 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.


Acasti Pharma logo

About Acasti Pharma

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
32
Year Founded
N/A

Sales & Book Value

Annual Sales
C$196,000.00
Cash Flow
C$2.37 per share
Book Value
C$2.05 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
C$101.86 million
Next Earnings Date
11/15/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Acasti Pharma (CVE:ACST) Frequently Asked Questions

What stocks does MarketBeat like better than Acasti Pharma?

Wall Street analysts have given Acasti Pharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acasti Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Acasti Pharma's next earnings date?

Acasti Pharma is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Acasti Pharma
.

How has Acasti Pharma's stock price been impacted by COVID-19?

Acasti Pharma's stock was trading at C$0.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACST stock has increased by 325.9% and is now trading at C$2.30.
View which stocks have been most impacted by COVID-19
.

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the following people:
  • Ms. Janelle D'Alvise, Pres, CEO, Corp. Sec. & Director (Age 65, Pay $428.04k)
  • Dr. Pierre Lemieux, Co-Founder, COO & Chief Scientific Officer (Age 56, Pay $276.38k)
  • Mr. Brian D. Ford CPA, CA, Chief Financial Officer (Age 62, Pay $364.82k)

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), Aurora Cannabis (ACB), SCYNEXIS (SCYX), Square (SQ), Nokia (NOK), Axsome Therapeutics (AXSM), Blink Charging (BLNK), Inovio Pharmaceuticals (INO), Okta (OKTA) and Tesla (TSLA).

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ACST."

How do I buy shares of Acasti Pharma?

Shares of ACST and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately C$2.30.

How much money does Acasti Pharma make?

Acasti Pharma has a market capitalization of C$101.86 million and generates C$196,000.00 in revenue each year.

How many employees does Acasti Pharma have?

Acasti Pharma employs 32 workers across the globe.

What is Acasti Pharma's official website?

The official website for Acasti Pharma is www.acastipharma.com.

Where are Acasti Pharma's headquarters?

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The company can be reached via phone at +1-450-6864555.


This page was last updated on 10/21/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.